Antimetabolite drugs were the first widely successful class of drugs developed by rational design for the treatment of cancer [Articles:18860765, 14803432]. They include analogues of purines (thiopurines such as 6-mercaptopurine, 6-thioguanine and azathioprine) pyrimidines (fluoropyrimidines such as 5-fluorouracil, tegafur and capecitabine) and antifolates (methotrexate, pemetrexed and raltitrexed). Although some were designed in the 1950's these drugs are still used today in treatment of leukemia, breast cancer, colorectal cancer and many other cancers [Article:2679902]. Some of these drugs, for example methotrexate and azathioprine, are also used in the management of inflammatory conditions such as rheumatoid arthritis.
The purpose of this pathway is to show how the pharmacodynamics (PD) for many of the antimetabolite drugs are interconnected. The figure links various antimetabolite drugs and shows how their actions overlap. In order to increase efficacy, antimetabolite drugs are commonly used in combination with other antineoplastic drugs including sometimes other antimetabolites (eg. Methotrexate and 6-mercaptopurine for treatment of ALL) although care much be taken to avoid overlapping side effect profiles [Article:11008002]. Normal intermediates, such as Leucovorin, can also be used to enhance antimetabolite drug action [Article:1911453]. All the antimetabolite drugs depicted here interact in some way with the folate cycle also known as folate-mediated one-carbon metabolism [Articles:16207145, 19952870]. Folate-mediated one-carbon metabolism is essential for synthesis of DNA and activated methyl groups that are required for DNA methylation, regulation of chromatin structure, remethylation of homocysteine as well as methylation of proteins and drugs [Article:19812215]. Disturbance of the folate cycle, whether by inadequate vitamin intake, or variants effecting expression or activity of the genes and products involved, has been associated with a variety of disease conditions including neural tube defects in developing embryos, vascular diseases, cognitive disorders and cancers, reviewed in [Article:11683553]. It is because the folate cycle is so critical for DNA synthesis and cellular functions, that it is a good target for antineoplastic drugs, however it may also be responsible for the drugs adverse effects.
Folate is absorbed from the diet, from green leafy vegetables and as folic acid from supplements or enriched foods. Metabolism of folate to different forms can take place in different cell compartments including the cytoplasm (as shown above), mitochondrion and nucleus (not depicted). Metabolism occurs as part of large multienzyme complexes that perform specific parts of the cycle, reviewed in [Article:19812215].
There are well known variants for many of the genes involved in the folate pathway including: TYMS:TSER (rs34743033), TYMS:1494del TTAAAG (rs34489327), TYMS:TSER*3G>C (no rs#), DHFR:19bpdel (rs70991108), MTHFR:677C>T (rs1801133), MTHFR:1298A>C (rs1801131), MTR:Asp919Gly (rs1805087), MTRR:66A>G (rs1801394), CBS:844ins68 (no rs#) [Article:19581920].
However, there are currently no guidelines for pharmacogenomic testing involving any of the genes depicted in this pathway (TPMT testing is suggested for thiopurines but this gene is not directly involved in the folate pathway). Several of these variants in the folate pathway are also associated with disease conditions such as neural tube defects and cardiovascular disorder. For more details on these variants and their PGx implications see the VIP and variant annotations and the individual drug pathways:
Very Important Pharmacogene Methylenetetrahydrofolate reductase (MTHFR)
Very Important Pharmacogene Thymidylate synthase (TYMS)
Annotated variants for Dihydrofolate reductase (DHFR)
Annotated variants for Methionine synthase (MTR)
Annotated variants for Methionine synthase reductase (MTRR)
Annotated variants for Methylenetetrahydrofolate dehydrogenase (MTHFD1)
Annotated variants for Cystathionine beta synthase (CBS)
Fluoropyrimidine Pathway (PD, PK)
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
If you would like to reproduce this PharmGKB pathway diagram, send an email to email@example.com to request permission. In your request, include the name of the pathway diagram you would like to use and provide a description of the purpose.
Entities in the Pathway
Relationships in the Pathway
|Arrow From||Arrow To||Controllers||PMID|
|5,10-methylenetrahydrofolate||5-methyl tetrahyrofolate||MTHFR||14647408, 15797993, 19812215|
|5,10-methylenetrahydrofolate||dihydrofolate||TYMS||11986237, 12084458, 12604405, 19812215, 19902562|
|5-methyl tetrahyrofolate||tetrahydrofolate||cyanocobalamin, MTR, MTRR||19812215|
|DHFR||DHFR||methotrexate, pemetrexed||12084458, 14662327, 16637794|
|dihydrofolate||tetrahydrofolate||DHFR||12084458, 14529544, 19812215|
|homocysteine||methionine||cyanocobalamin, MTR, MTRR||15797993, 17611986, 19812215|
|IMP||IMP||Black Box: de novo purine synthesis|
|PPAT||PPAT||methotrexate, purine analogues||10432311, 5788533, 9744080|
|TYMS||TYMS||leucovorin, methotrexate, pemetrexed, Pyrimidine analogues, raltitrexed||12084458, 12724731, 12819937, 15638735, 16637794|
Download data in TSV format. Other formats are available on the Downloads/LinkOuts tab.
|Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pacific journal of cancer prevention : APJCP. 2012. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan, Icli Fikri.|